Novel pharmacologic treatment attenuates septic shock and improves long-term survival

Surgery (United States)

Volumn 154, Issue 2, 2013, Pages 206-213

  Zhao, Ting ^a   Li, Yongqing ^a   Liu, Baoling ^a,b   Liu, Zhengcai ^a,c   Chong, Wei ^a,d   Duan, Xiuzhen ^e   Deperalta, Danielle K ^a   Velmahos, George C ^a   Alam, Hasan B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE MARROW; CONTROLLED STUDY; CYTOKINE RESPONSE; LIVER INJURY; LONG TERM SURVIVAL; MACROPHAGE; MOUSE; NONHUMAN; PERITONEAL FLUID; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL;

ACUTE LUNG INJURY; ANIMALS; CELLS, CULTURED; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; SHOCK, SEPTIC; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880859481     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2013.04.003     Document Type: Article

References (25)

1. J.S. Boomer, K. To, K.C. Chang, O. Takasu, D.F. Osborne, and A.H. Walton Immunosuppression in patients who die of sepsis and multiple organ failure JAMA 306 2012 2594 2605
2. V.M. Ranieri, B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, and S. Finfer Drotrecogin alfa (activated) in adults with septic shock N Engl J Med 366 2012 2055 2064
3. R.P. Wenzel, and M.B. Edmond Septic shock - evaluating another failed treatment N Engl J Med 366 2012 2122 2124
4. B.A. Suliman, D. Xu, and B.R. Williams HDACi: molecular mechanisms and therapeutic implications in the innate immune system Immunol Cell Biol 90 2012 23 32
5. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552 (Pubitemid 47255934)
6. M.R. Shakespear, M.A. Halili, K.M. Irvine, D.P. Fairlie, and M.J. Sweet Histone deacetylases as regulators of inflammation and immunity Trends Immunol 32 2011 335 343
7. M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, and C. Kelly Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 2007 31 39 (Pubitemid 46053039)
8. F. Leoni, A. Zaliani, G. Bertolini, G. Porro, P. Pagani, and P. Pozzi The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines Proc Natl Acad Sci U S A 99 2002 2995 3000 (Pubitemid 34240574)
9. Y. Li, B. Liu, E.Y. Fukudome, A.R. Kochanek, R.A. Finkelstein, and W. Chong Surviving lethal septic shock without fluid resuscitation in a rodent model Surgery 148 2010 246 254
10. Y. Li, B. Liu, H. Zhao, E.A. Sailhamer, E.Y. Fukudome, and X. Zhang Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents Shock 32 2009 517 523
11. Y. Li, B. Liu, X. Gu, A.R. Kochanek, E.Y. Fukudome, and Z. Liu Creating a "pro-survival" phenotype through epigenetic modulation Surgery 152 2012 455 464
12. J. Weischenfeldt, and B. Porse Bone marrow-derived macrophages (BMM): isolation and applications CSH Protoc 2008 2008 pdb prot5080
13. D.R. McIlwain, P.A. Lang, T. Maretzky, K. Hamada, K. Ohishi, and S.K. Maney iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS Science 335 2012 229 232
14. G. Liu, A. Friggeri, Y. Yang, Y.-J. Park, Y. Tsuruta, and E. Abraham miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses Proc Natl Acad Sci USA 106 2009 15819 15824
15. W. Chong, Y. Li, B. Liu, T. Zhao, E.Y. Fukudome, and Z. Liu Histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates Toll-like receptor 4 signaling in lipopolysaccharide-stimulated mouse macrophages J Surg Res 178 2012 851 859
16. D. Rittirsch, M.S. Huber-Lang, M.A. Flierl, and P.A. Ward Immunodesign of experimental sepsis by cecal ligation and puncture Nat Protoc 4 2009 31 36
17. J. Kawada, P. Zou, R. Mazitschek, J.E. Bradner, and J.I. Cohen Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis J Biol Chem 284 2009 17102 17109
18. T.H. Kim, S.J. Yoon, and S.M. Lee Genipin attenuates sepsis by inhibiting Toll-like receptor signaling Mol Med 18 2012 455 465
19. D. Rittirsch, M.A. Flierl, and P.A. Ward Harmful molecular mechanisms in sepsis Nat Rev Immunol 8 2008 776 787
20. K. Takeda, and S. Akira TLR signaling pathways Semin Immunol 16 2004 3 9 (Pubitemid 38147427)
21. H. Weighardt, G. Jusek, J. Mages, R. Lang, K. Hoebe, and B. Beutler Identification of a TLR4- and TRIF-dependent activation program of dendritic cells Eur J Immunol 34 2004 558 564 (Pubitemid 39255965)
22. A. Kimura, T. Naka, T. Nakahama, I. Chinen, K. Masuda, and K. Nohara Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses J Exp Med 206 2009 2027 2035
23. O.H. Kramer, D. Baus, S.K. Knauer, S. Stein, E. Jager, and R.H. Stauber Acetylation of Stat1 modulates NF-kappaB activity Genes Dev 20 2006 473 485 (Pubitemid 43244401)
24. W. Chong, Y. Li, B. Liu, Z. Liu, T. Zhao, and D.R. Wonsey Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study J Trauma Acute Care Surg 72 2012 347 353 discussion 53-4
25. R.A. Finkelstein, Y. Li, B. Liu, F. Shuja, E. Fukudome, and G.C. Velmahos Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock J Surg Res 163 2010 146 154